TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

June 28, 2023 at 15:49 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.

The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide.

Contact Details

Proactive USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/transcode-therapeutics-making-preclinical-progress-with-lead-metastatic-cancer-candidate-175829166

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	248.92	+0.92 (0.37%)
AAPL	343.00	-4.72 (-1.36%)
AMD	531.99	+15.20 (2.94%)
BAC	50.77	+0.20 (0.41%)
GOOG	314.51	-2.76 (-0.87%)
META	633.96	-8.66 (-1.35%)
MSFT	531.95	+7.44 (1.42%)
NVDA	216.16	+5.20 (2.47%)
ORCL	125.80	-0.36 (-0.29%)
TSLA	394.30	+22.08 (5.93%)

Symbol

Price

Change (%)

AMZN

248.92

+0.92 (0.37%)

AAPL

343.00

-4.72 (-1.36%)

AMD

531.99

+15.20 (2.94%)

BAC

50.77

+0.20 (0.41%)

GOOG

314.51

-2.76 (-0.87%)

TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

Contact Details

More News

Recent Quotes